$ALMS insider trading
Over the last 12 months, Alumis insiders reported 10 buys totaling $39.0M and 14 sales totaling $1.6M across SEC Form 4 filings.
- Bought · 12m
- $39.0M 10 events
- Sold · 12m
- $1.6M 14 events
- Events · 12m
- 24 Form 4 filings, grouped
- Insiders · 12m
- 10 distinct reporters
- 10b5-1 share
- 0% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Decision | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Schroer John R.Chief Financial Officer · O | ▼ Sale | Non-discretionarytax on vesting | 794 | $6.52 | $5K | -3.2% | — |
| Nov 2, 2026 | Pangali SanamChief Legal Officer · O | ▼ Sale | Non-discretionarytax on vesting | 332 | $6.52 | $2K | -3.4% | — |
| Nov 2, 2026 | Hardiman Roy C.Chief Business & Strategy Ofcr · O | ▼ Sale | Non-discretionarytax on vesting | 652 | $6.52 | $4K | -0.3% | — |
| Nov 2, 2026 | Goldstein David MChief Scientific Officer · O | ▼ Sale | Non-discretionarytax on vesting | 629 | $6.52 | $4K | -2% | — |
| Nov 2, 2026 | Drappa JornChief Medical Officer · O | ▼ Sale | Non-discretionarytax on vesting | 593 | $6.52 | $4K | -1% | — |
| Nov 2, 2026 | Bradley Mark ChristopherChief Development Officer · O | ▼ Sale | Non-discretionarytax on vesting | 623 | $6.52 | $4K | -1.3% | — |
| Sep 8, 2026 | AKKARAJU SRINIVASD | ▼ Sale | Discretionaryopen market | 96,131 | $10.55 | $1.0M | -4.5% | 2 tranches · indirect |
| Sep 8, 2026 | AKKARAJU SRINIVASD | ▲ Buy | — | 986,721 | $10.87 | $10.7M | +75.2% | 4 tranches · indirect |
| Aug 3, 2026 | Schroer John R.Chief Financial Officer · O | ▼ Sale | Non-discretionarytax on vesting | 3,282 | $26.37 | $87K | -11.7% | — |
| Aug 3, 2026 | Pangali SanamChief Legal Officer · O | ▼ Sale | Non-discretionarytax on vesting | 1,364 | $26.37 | $36K | -12.3% | — |
| Aug 3, 2026 | Hardiman Roy C.Chief Business & Strategy Ofcr · O | ▼ Sale | Non-discretionarytax on vesting | 2,692 | $26.37 | $71K | -1.3% | — |
| Aug 3, 2026 | Goldstein David MChief Scientific Officer · O | ▼ Sale | Non-discretionarytax on vesting | 2,596 | $26.37 | $68K | -7.7% | — |
| Aug 3, 2026 | Drappa JornChief Medical Officer · O | ▼ Sale | Non-discretionarytax on vesting | 2,447 | $26.37 | $65K | -4.1% | — |
| Aug 3, 2026 | Bradley Mark ChristopherChief Development Officer · O | ▼ Sale | Non-discretionarytax on vesting | 2,572 | $26.37 | $68K | -5% | — |
| Jul 6, 2026 | Pangali SanamChief Legal Officer · O | ▼ Sale | Discretionaryexercise and sell | 5,000 | $28 | $140K | -31% | — |
| Jan 9, 2026 | AKKARAJU SRINIVASD | ▲ Buy | — | 588,235 | $17 | $10.0M | +46.5% | indirect |
| Jan 8, 2026 | Foresite Labs, LLC10% | ▲ Buy | — | 411,764 | $17 | $7.0M | +16.5% | co-filed copy · 2 tranches · indirect |
| Jan 8, 2026 | Foresite Capital Management VI LLC10% | ▲ Buy | — | 411,764 | $17 | $7.0M | +16.5% | co-filed copy · 2 tranches · indirect |
| Jan 8, 2026 | Tananbaum James B.D·10% | ▲ Buy | — | 411,764 | $17 | $7.0M | +16.5% | 2 tranches · indirect |
| Dec 5, 2025 | AKKARAJU SRINIVASD | ▲ Buy | — | 186,377 | $9.84 | $1.8M | +17.3% | 3 tranches · indirect |
| Dec 4, 2025 | AKKARAJU SRINIVASD | ▲ Buy | — | 262,027 | $7.79 | $2.0M | +32.1% | 3 tranches · indirect |
| Dec 1, 2025 | AKKARAJU SRINIVASD | ▲ Buy | — | 173,589 | $7.55 | $1.3M | +27% | 3 tranches · indirect |
| Nov 21, 2025 | Foresite Capital Management VI LLC10% | ▲ Buy | — | 72,212 | $7.38 | $533K | +2.8% | co-filed copy · indirect |
| Nov 21, 2025 | Tananbaum James B.D·10% | ▲ Buy | — | 72,212 | $7.38 | $533K | +2.8% | indirect |
| Nov 21, 2025 | Foresite Labs, LLC10% | ▲ Buy | — | 72,212 | $7.38 | $533K | +2.8% | co-filed copy · indirect |
| Nov 20, 2025 | AKKARAJU SRINIVASD | ▲ Buy | — | 125,743 | $7.2 | $905K | +24.3% | indirect |
| Nov 19, 2025 | AKKARAJU SRINIVASD | ▲ Buy | — | 241,338 | $6.34 | $1.5M | +87.4% | 3 tranches · indirect |
| Nov 19, 2025 | Foresite Labs, LLC10% | ▲ Buy | — | 507,874 | $6.09 | $3.1M | +25% | co-filed copy · 4 tranches · indirect |
| Nov 19, 2025 | Foresite Capital Management VI LLC10% | ▲ Buy | — | 507,874 | $6.09 | $3.1M | +25% | co-filed copy · 4 tranches · indirect |
| Nov 19, 2025 | Tananbaum James B.D·10% | ▲ Buy | — | 507,874 | $6.09 | $3.1M | +25% | 4 tranches · indirect |
| Nov 13, 2025 | AKKARAJU SRINIVASD | ▲ Buy | — | 276,179 | $5.25 | $1.4M | — | indirect |
Every $ALMS filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Alumis filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ALMS feed.